今年6月22日,科济药业(02171.HK)的恺力美作为全球首款治疗实体瘤的CAR-T细胞产品获批国内上市,用于晚期胃癌治疗,但售价高达99万元,究竟会有多少患者愿意买单?随着公司半年报披露,该问题受到投资者关注。 8月19日上午,科济药业在业绩会上表示,恺力美已在北京高博医院开出全国首张临床处方,复旦大学附属中山医院已完成全球首例患者的细胞采集,嘉会国际肿瘤中心已完成首例外籍患者的T细胞采集。...
Source Link今年6月22日,科济药业(02171.HK)的恺力美作为全球首款治疗实体瘤的CAR-T细胞产品获批国内上市,用于晚期胃癌治疗,但售价高达99万元,究竟会有多少患者愿意买单?随着公司半年报披露,该问题受到投资者关注。 8月19日上午,科济药业在业绩会上表示,恺力美已在北京高博医院开出全国首张临床处方,复旦大学附属中山医院已完成全球首例患者的细胞采集,嘉会国际肿瘤中心已完成首例外籍患者的T细胞采集。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.